

"The added value of ^{18}F -FDG PET/CT in the assessment of onset and steroid resistant polymyalgia rheumatica"

Patricia Moya Alvarado¹, Alejandro Fernandez Leon², Maria Emilia Corica³, Valle Camacho Marti², Diego Alfonso López-Mora², Ivan Castellví Barranco¹, Hèctor Corominas¹

¹ Department of Rheumatology, Hospital Santa Creu i Sant Pau, Barcelona, Spain.

² Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

³ Department of Rheumatology, Hospital José N. Lencinas. Mendoza, Argentina.

* Corresponding author

E-mail: pmoyaa@santpau.cat (PMA)

Abstract

PMR is a common inflammatory rheumatic disease. Although its clinical characteristics are fully recognized, no specific test for its diagnosis has been established to date. Several studies have described a wide variety of diseases that present with polymyalgic symptoms. A ^{18}F -FDG-PET/CT scan could help to deal with these differential diagnoses. The goal of our study is to describe the findings of the ^{18}F -FDG-PET/CT scan in a cohort of PMR patients and to detail how the ^{18}F -FDG-PET/CT scan improves accuracy when diagnosing other underlying conditions. This cross-sectional study enrolled patients with a diagnosis of PMR who underwent to a ^{18}F -FDG-PET/CT scan to rule out other diagnosis. The ^{18}F -FDG-PET/CT scan was performed either following clinical criteria at the onset of clinical symptoms or when the patient became PMR steroid resistant. Patients' demographic, clinical and analytical data at the moment of the ^{18}F -FDG-PET/CT scan were recorded. The final diagnosis was confirmed according to clinical judgement. A total of 103 patients with PMR were included. In 49.51% of patients, the ^{18}F -

PET/CT scan was ordered to study resistance to steroid therapy. The final diagnoses of patients were PMR in 70.9% patients, large vessel vasculitis in 15.5%, neoplasms 4.8% and another diagnosis in the rest. The ^{18}F FDG-PET/CT scan is a very useful technique for the study of Polymyalgia Rheumatica, not only to help in the diagnostic process, but also due to its role in the identification of a variety of PMR-like patrons.

Introduction

Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatic disease in patients over 50 years of age. Although the cause of PMR remains unknown, evidence consistently suggests a multifactorial etiology leading to an immunomediated process^{1,2}. Although PMR's clinical characteristics are fully recognized, no specific test for its diagnosis has been confirmed to date. Several studies have described a wide variety of diseases that present with polymyalgic symptoms^{2-4,5,6} and it is important to rule out all these processes, since their therapy and prognosis differ widely from the classic therapy used for PMR. Moreover, an association between PMR and giant cell arteritis (GCA) has been described. Approximately 50% of patients with GCA present with the clinical symptoms of PMR⁷. The percentage of patients with PMR who present GCA ranges from five to thirty percent depending on the series^{3,8}. In one population-based study, a temporal artery biopsy yielded positive histologic findings of GCA in 9% of patients presenting with typical PMR without any clinical manifestation of GCA⁹.

Imaging tests could help in these differential diagnoses. These tests have gained significant prominence since the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) launched new classification criteria that take ultrasonography findings into account¹⁰. Other imaging techniques that could help in the differential diagnosis of PMR are magnetic resonance imaging (MRI) and 18-fluorodeoxyglucose positron emission tomography (^{18}F FDG-PET/CT). ^{18}F FDG-PET/CT is a diagnostic imaging technique that measures metabolic activity by locating and quantifying glucose consumption. It has been used to diagnose and monitor neoplastic processes, though other specialties are now using it to study clinical symptoms such as fever of unknown origin and other processes of an inflammatory nature. The recognized use of a ^{18}F FDG-PET/CT scan to study pathologies characterized by high glucidic metabolism suggests that it may be a promising technique in the differential diagnostic

study of patients with PMR. ^{18}F FDG-PET/CT scan findings in PMR may include increased ^{18}F FDG uptake in shoulder, hip and spinous processes^{1,11}. A small number of series of published cases also describe subclinical vasculitis and other pathological entities of malignant origin in the ^{18}F FDG-PET/CT scans of patients with PMR. Nevertheless, the conclusive diagnostic relevance of this technique is as yet unknown when performed to complete the study of patients with clinical PMR.

Considering all these factors, the goal of our study was to examine the findings of ^{18}F FDG-PET/CT scans in a cohort of PMR patients and to determine whether this imaging technique offers the clinician the possibility of diagnosing underlying conditions.

Material and methods

Patient groups and clinical assessment

A cross-sectional retrospective study was performed in a cohort of PMR patients at the Department of Rheumatology at a tertiary university hospital. Between April 2011 and April 2018, we enrolled patients who had undergone an ^{18}F FDG-PET/CT scan to rule out other diagnoses. PMR was diagnosed by a rheumatologist in accordance with the ACR/EULAR 2012 classification criteria¹⁰ in all patients included in the study. The study population was classified into two groups: 1) patients with onset PMR (PMR_{os}), and 2) patients with PMR who were refractory to glucocorticoid therapy (PMR_{sr}). The first group was defined as patients who were visited in the rheumatology department during the initial diagnostic process or who underwent a ^{18}F FDG-PET/CT scan within six weeks after the diagnosis of PMR. The second group was defined as patients with PMR who did not respond to conventional treatment with steroids or patients who flared when the dose was below 7.5 mg. The criteria for performing the ^{18}F FDG-PET/CT scan were: 1) PMR_{os}: all patients who presented an onset PMR and were attended by one of the three main investigators (JM, EC, PM); and, 2) PMR_{sr}: all patients with PMR who were refractory to glucocorticoid therapy independently of which physician attended them. We excluded patients who had a history of neoplasia before the ^{18}F FDG-PET/CT scan was performed.

Upon admission to the study, we collected patients' demographic, clinical and laboratory data. ^{18}F FDG-PET/CT scan variables collected were: the joint involved (shoulders, hips, peripheral joints) and aorta, PET/CT standardized uptake values (SUV), and the tissue to background ratio (TBR) of each location according to the average activity of the vena cava. ^{18}F FDG-PET/CT images were analyzed by a qualified nuclear medicine specialist.

The final confirmed diagnosis was accepted according to the physician's opinion considering the following combination of data: a) clinical parameters, b) the results of the supplemental examinations (blood test and ^{18}F FDG-PET/CT scan), and c) the outcome of the disease.

The study was approved by the local institutional ethics committee (IIBSP-VAS-2013-122) and all patients signed an informed consent form before enrollment.

^{18}F FDG-PET/CT assessment

All patients had fasted for at least six hours before ^{18}F FDG administration. After the intravenous injection of ^{18}F FDG (3.7 MBq/kg), they rested for 60 minutes. Images were acquired using a GEMINI PET/CT scanner (PHILIPS Health Systems Amsterdam Holland), integrated with a 64-slice multidetector CT.

PET images were obtained for 180 seconds per position. To attenuate correction and to identify anatomical location, we performed a low-dose, non-contrast-enhanced CT scan (tube voltage: 120kV; effective tube current: 30–100 mA), which included the whole body from the top of the skull to the feet.

Image Analysis

It was difficult to discriminate between synovitis and perisynovitis involvement at ^{18}F FDG uptake sites in the shoulder region using ^{18}F FDG/CT. Therefore, we did not classify shoulder lesions as synovitis or perisynovitis, and all sites thought to correspond to such lesions were regarded as the "shoulder".

^{18}F FDG uptake was assessed in large arteries, proximal joints (shoulders, hips and sternoclavicular joints) and in extraarticular synovial structures (interspinous, ischiogluteal and praepubic bursae). We used the semi-quantitative values of SUV in each vascular and articular

structure. Vascular SUVmax measurements were taken drawing a VOI (volume region of Interest) at the level of the most visually active segment of the aorta and at the same level as the cava venous pool. Articular and synovial VOIs were also evaluated in order to measure the SUV value, taking into account the maximum activity uptake area. Activity was normalized using TBR values (target-to-blood pool ratio) to divide the vascular wall SUV by the venous blood pool SUV to correct for blood uptake.

Statistical analysis

All data are expressed as mean \pm standard deviation (SD). Categorical variables are presented as absolute frequencies and percentages. Comparisons between independent means were analyzed using the Student's t-test or the Mann-Whitney test using IBM-SPSS, version 25. For the categorical variables, the chi-square test or Fisher's exact test were used as appropriate. Correlations between quantitative variables were analyzed using Pearson's correlation coefficient. The non-parametric test (Kruskal-Wallis) was used for quantitative variables without a normal distribution. The Mann-Whitney U test was used in the post-hoc study. The level of statistical significance was established at 5% (alpha value = 0.05).

Results

A total of 103 patients with PMR (30 men and 73 women) were included in the study. The average age of the patients was 72.48 ± 9.01 years. In 52 (50.48%) patients, the ^{18}F FDG-PET/CT scan was performed at the onset of the disease based on clinical opinion. In 51 (49.51%) patients, the ^{18}F FDG-PET/CT scan was requested to study PMR refractory to glucocorticoids. The average dose of steroids (prednisone or equivalent) at the time of scanning was 11.78 ± 1.36 mg orally daily. Table 1 shows patients' clinical characteristics at the time of the ^{18}F FDG-PET/CT scan.

Table 1: Clinical characteristics of patients at the time of ^{18}F FDG-PET/CT

Patient's clinical features	
Women, n (%)	73 (70.9 %)

Age (years), mean \pm SD	72.4 \pm 9.0
Disease duration (months), mean \pm SD	24 \pm 41.9
Asthenia, n (%)	66 (64.1%)
Weight loss, n (%)	38 (36.9%)
Fever, n (%)	16 (15.5%)
Morning stiffness, n (%)	49 (47.6%)
Cervicalgia, n (%)	71 (68.9%)
Shoulder pain, n (%)	100 (97.1%)
Hip pain, n (%)	89 (86.4%)
Arthralgia, n (%)	26 (25.2%)
Headache, n (%)	23 (22.3%)
Amaurosis, n (%)	5 (4.9%)
Jaw claudication, n (%)	9 (8.7%)
Temporal artery tenderness, n (%)	2 (1.9%)
Reactive C protein (mg/L), mean \pm SD	38.0 \pm 69.5
Erythrocyte sedimentation rate (mm/s), mean \pm SD	55.9 \pm 31.0
Hemoglobin (g/L), mean \pm SD	118.7 \pm
Prednisone dose (MPD), mean \pm SD	11.7 \pm 1.3
Duration of PDN before PET/CT (weeks), Median	13
- PMR_os (weeks), Median	2.7
- PMR_sr (weeks), Median	61.1

The final diagnosis, taking into account the results of the 18 F-DG-PET/CT scan, analytical parameters and clinical outcome, was PMR in 73 (70.9%) patients, large vessel vasculitis (LVV) in 16 (15.5%), neoplasms in five (4.8%) and other diagnosis (PMR with elderly-onset rheumatoid arthritis [EORA], Sjögren's syndrome, small vessel vasculitis and degenerative process) in the rest of the sample.

Table 2 shows the TBR of the various locations according to the final diagnosis. We found significant differences between the TBR of the aorta in LVV patients and the other patients ($p <$

0.001). In the posthoc study, statistical significance was maintained between the final diagnosis of LVV and the TBR in the aorta ($p= 0.002$).

When analyzing clinical and analytical variables, we observed significant differences between the group with PMR as a final diagnosis and the patients with other diagnoses for the variables of weight loss (28.8 % vs 56.7 %; $p = 0.013$) and amaurosis (1.4% versus 13.3%; $p = 0.024$).

Table 2: TBR of the different locations according to the final diagnosis. TBR_bursae:

Includes trochanteric and subacromial bursitis.

Final diagnosis	TBR_shoulder	TBR_column	TBR_joint	TBR-aorta	TBR_bursae
PMR	2.03±0.9	1.78±0.9	2.74±1.09	1.52±0.217	2.42±0.91
LVV	1.80±0.55	1.95±1.05	2.51±0.77	1.98±0.64	2.77±1.07
NEOPLASIA	1.60±0.69	1.40±0.67	1.58±.	1.46±0.22	1.33±.
OTHER	2.38±0.94	1.90±0.79	3.12±2.07	1.92±0.42	3.085±0.6
p	P=0.370	P=0.472	P=0.516	P=<0.001	P=0.104

¹⁸FDG-PET/CT in PMR & Large vessel vasculitis

Forty (54.8%) of the patients diagnosed with PMR showed increased glucidic metabolism in the shoulder, 27 (37%) in the hips, 23 (31.5%) in other joints, and 34 (46.6%) in one or more bursa (Fig 1). Of the 23 patients with joint uptake in the ¹⁸FDG-PET/CT scan, the area most frequently affected was the sternoclavicular (23.28%), followed by the knees (10.95%) and the wrist (8.21%).

Fig 1. ¹⁸FDG-PET/CT images. 1A: Uptake in shoulders and cervical interspinous bursae.1B: Uptake in supra- and infra-diaphragmatic aorta.

Of the 16 patients diagnosed with LVV, in addition to glucidic uptake increase in the aortic wall, ¹⁸FDG PET/CT scans showed a concomitant uptake in the shoulders, hips and bursae. We did not measure vascular diameters in the patients with PMR included in the study. Nevertheless, in the visual evaluation, we did not observe dilated vessels. Table 3 shows the sites of ¹⁸FDG accumulations in patients with PMR and LVV.

Table 3: Distribution of glycemetic metabolism intake in patients diagnosed with polymyalgia rheumatica (PMR) and large vessel vasculitis (LVV) . Table shows distribution of glycemetic metabolism intake in all patients in the sample diagnosed with PMR (n = 73) or LVV (n = 16).

Glycemetic metabolism intake in PMR and/or Vasculitis	N (%)
PMR	73 (70.9)
Shoulder involvement	40 (54.8)
Hip involvement	27 (37.0)
Peripheral joints	23 (31.5)
- Sternoclavicular	17 (23.2)
- Knee	6 (8.2)
- Wrist	8 (10.9)
Bursae uptake	34 (46.6)
- Bursae cervical spine	22 (30.1)
- Bursae dorsal spine	3 (4.1)
- Bursae lumbar spine	25 (34.2)
- Ischiatic bursae	26 (35.6)
LVV	16 (15.5)
Shoulder involvement	9 (56.3)
Hip involvement	6 (37.5)
Bursae uptake	11 (68.8)
- Bursae cervical spine	9 (56.3)
- Bursae lumbar spine	11 (68.8)
- Ischiatic bursae	6 (37.5)

Malignancies

Of the five patients who were finally diagnosed with neoplastic processes (four haematological and one transverse colon) and who first presented with PMR, the ¹⁸F-DG-PET/CT scan showed accumulations suggestive of neoplastic process in three patients (mediastinal lymphadenopathy

and increased diffuse glucidic metabolism in bone marrow in two patients with lymphoproliferative syndrome, along with a hypermetabolic lesion in the transverse colon with the diagnosis of a high-grade villous adenoma in the third patient). The ¹⁸FDG-PET/CT scan thus helped diagnose three of the 103 patients who had neoplastic processes.

¹⁸FDG-PET/CT in onset PMR versus PMR refractory to glucocorticoids

When we performed the statistical analysis and compared the clinical variables of patients with PMR_{os} and patients with PMR_{sr}, we observed that the former presented more asthenia, weight loss and fever than the latter group. We did not find differences in waist pain, cervicalgia or analytical parameters. Table 4 shows the statistical differences observed in patients with PMR_{os} and patients with PMR_{sr}.

Table 4. Clinical features of patients: a) with onset PMR vs steroid resistant PMR b) with the final diagnosis of PMR, LVV or malignancy. PMR_{os}: onset PMR patients; PMR_{sr}: steroid resistant PMR patients; PMR global: PMR_{os} and PM_{sr}, LVV: large vessel vasculitis

	PMR global	LVV	Malignancies	PMR_{os}	PMR_{sr}	p
Women, n (%)	23 (31.5%)	4 (25%)	2 (40.0%)	33 (63.5 %)	40 (78.4%)	0.129
Asthenia, n (%)	49 (67.1%)	11 (68.8%)	3 (60.0%)	40(76.9 %)	26 (51.0%)	0.006*
Weight loss, n (%)	21 (28.7%)	10 (62.5%)	4 (80.0%)	25 (48.1%)	13 (25.5%)	0.017*
Fever, n (%)	11 (15.1%)	2 (12.5%)	0 (0%)	12 (23.1%)	4 (7.8%)	0.029*
Morning stiffness, n (%)	38 (52.1%)	6 (37.5%)	2 (40.0%)	27 (51.9%)	22 (43.1%)	0.37
Cervicalgia, n (%)	52 (71.2%)	12 (75 %)	2 (40.0%)	34 (65.4%)	37 (72.5 %)	0.432
Shoulder pain, n (%)	71 (97.3%)	15 (93.8 %)	5 (100%)	51 (98.1%)	49 (96.1%)	0.543

Hip pain, n (%)	66 (90.4%)	11(68.8 %)	5 (100%)	48 (92.3 %)	41 (80.4%)	0.074
Headache, n (%)	13 (17.8%)	7 (43.8%)	1 (20.0.%)	11 (21.2%)	12 (23.5%)	0.772
Amaurosis, n (%)	1 (1.4%)	4 (25%)	0 (0%)	2 (3.8 %)	3 (5.9 %)	0.630
Jaw claudication, n (%)	4 (5.5%)	5 (31.3%)	0 (0.0%)	4 (7.7 %)	5 (9.8%)	0.704
Reactive C protein (mg/L), mean ± SD	29.7±46.1	43.3±45.3	48.9±72.17	44.8 ± 59.5	31.1 ± 78.3	0.287
Erythro sedimentation (mm/s), mean ± SD	53.2±3.1	69.3±28	59±39.8	59.3 ± 29.4	52.4 ± 32.5	0.663
Hemoglobin (g/L), mean ± SD	120.3±25.4	116.8±12.1	118±9.01	117.4 ± 23.2	120.0 ± 26.7	0.880
Prednisone dose, mean ± SD	11.5±11.64	11.0±12.2	6.6±11.5	10.7 ± 11.9	11.4 ± 10.8	0.124

We classified the final diagnoses into four groups: PMR, LVV, neoplasms and other diagnoses (including PMR with EORA, Sjögren syndrome, small vessel vasculitis and a degenerative process). When we compared these final diagnoses considering whether they were PMR_{os} or PMR_{sr}, we found significant differences in the final diagnosis (p=0.045) (Table 5).

Table 5. Final diagnosis of patients with onset PMR (PMR_{os}) vs steroid resistant (PMR_{sr}). p=0.045. PMR: polymyalgia rheumatica; LVV: large vessel vasculitis

Final diagnosis	PMR	LVV	NEOPLASIA	OTHER
PMR _{os} , n (%)	37 (50.7)	6 (37.5)	5 (100)	4 (44.4)
PMR _{sr} , n (%)	36 (49.3)	10 (62.5)	0 (0)	5 (55.6)
Total	73	16	5	9

Discussion

The present study was designed to rule out a wide spectrum of differential diagnoses in a group of patients studied by ^{18}F FDG-PET/CT. We included 103 patients with an initial diagnosis of PMR. The confirmed diagnosis in our cohort was PMR in 70.9%, LVV in 15.5%, neoplasms in 4.8%, and other diagnoses in the remaining 8.8%.

Several studies corroborate the already known relationship between PMR and LVV studied by PET/CT scan. But unlike our study, the main objective of most of these studies was not to analyse the wide range of differential diagnoses presented by the PMR but to point out certain specificities of LVV and PMR. To date, few articles have addressed the issue of the broad range of differential diagnoses presented by PMR by PET/CT scan.

Henckaerts et al.¹² prospectively included 99 consecutive patients with a possible clinical diagnosis of PMR. All patients underwent ^{18}F FDG-PET scanning before treatment with steroids. As in our study, the gold standard for a diagnosis of PMR was the judgment of an experienced clinician. A final diagnosis of isolated PMR was made in 67.6% of the patients (as in our study), while another condition was diagnosed in the remaining 32.32% of patients. Diagnoses made in non-PMR patients were for a variety of diseases that can present with similar clinical symptoms.

Malignancies

In our cohort, five patients (4.8%) presented neoplastic processes (four hematological neoplasms and one transverse colon high-grade villous adenoma). The ^{18}F FDG-PET/CT scan helped diagnose malignant processes in three of the 103 patients included. Published data to date on this topic are scarce. In one recent paper, in a cohort of 99 patients with PMR, Henckaerts L et al.¹² found one patient who presented a paraneoplastic syndrome secondary to a carcinoid neoplasm (visible on PET scan). In another study, Palard Novello et al.¹³ studied 21 patients with “new onset PMR” in order to evaluate the use of the ^{18}F FDG-PET/CT scan in assessing tocilizumab treatment and found that one patient presented a malignant process in the ^{18}F FDG-PET/CT scan pre-treatment. In a large database study from the Swedish Hospital Discharge Register, Ji J et al.¹⁵ included 5,918 patients with GCA and PMR and reported a clear increased risk of cancer within the first year of PMR diagnosis. Similarly, Muller et al.¹⁴ described a 69% increased risk of malignancy in patients with PMR within the first six months of diagnosis. One explanation for the high risk observed in their study may be that the high rate of

health care consumption allowed for a higher rate of cancer detection. In contrast with the results of Ji J et al, several studies found no association¹⁴⁻¹⁸ with an increase in the risk of cancer after PMR diagnosis.

It is difficult to reach a firm conclusion or confirm this association because most studies included have a referral bias, a lack of control groups, and/or a limited follow up period. Although the association between PMR and malignant processes is well known, results from published articles and reviews do not offer consistent or strong evidence. Our data show a non-significant rate of malignant processes, but we cannot definitely conclude whether or not this rate is higher than that in the population without PMR because we did not have a control group.

Large vessel vasculitis

Multiple published papers describe the relationship between LVV and PMR studied by PET-CT, but the range of percentages of this association varies widely. For instance, Henckaerts et al.¹² described associations of around 2%, which is very different from the 65% described by Lavado-Perez et al. and Prieto-Peña et al.^{19,20}. Prieto-Peña studied 84 patients with classic PMR. A PET/CT scan was positive for LVV in 51 (60.7%) patients. The differences observed in the incidence of LVV described by Prieto-Peña²⁰ compared to our results could be explained by the differences in the populations studied. Prieto et al's patients were all steroid resistant. When classifying the patients in our sample as steroid-resistant or onset we observed that the frequency of LVV in the PMR_sr was 62.5% compared to 37.5% in the PMR_os group, suggesting a consistency with the results of the Prieto-Peña study.

Prieto-Peña also studied whether there was an association between LVV and clinical and analytical variables. They described that pelvic girdle pain, inflammatory low back pain and lower limb pain were predictors of a positive ¹⁸F-DG-PET/CT scan result for LVV in patients with PMR. However, they did not find an association with any analytical parameters or with the presence of constitutional symptoms. Like Prieto- Peña, we found no-significant association between LVV and PMR in patients who presented analytical alterations. Conversely, Gonzalez Gay et al.²¹ reported that patients with PMR associated with GCA had significant alterations in erythrocyte sedimentation rate, platelet count and hemoglobin compared to patients with isolated PMR.

Furthermore, as in Prieto-Peña et al's study., the work of Lavado-Perez et al.¹⁹ described 40 patients diagnosed with PMR using PET/CT scan who showed a high prevalence of LVV (65%), which is considerably higher than our prevalence. Once again, this difference could be explained by the fact that 33 of their 40 patients had suspected LVV before ¹⁸FDG-PET/CT, strengthening the notion that despite being PMR, the cohorts of patients studied and published to date with ¹⁸FDG-PET/CT scan are not homogenous.

In contrast, Henckaerts et al.¹² reported fewer cases of LVV than those described by previous studies. They found that only 15% of PMR patients had an increased FDG uptake in the larger thoracic vessels, compared with 6% of control patients. Of the patients with a vascular ¹⁸FDG uptake, two were diagnosed with GCA based on a positive temporal artery biopsy. They attributed these findings to blood pool activity or no activity in the vessel wall, and to defects in the technique in the collection of images in some of the scans.

Concerning TBR aorta data, in our cohort, the prevalence of TBR of the aorta in the patients included in the "other group" was similar to that in patients in the LLV group. There may be several plausible explanations for this. The first is the small size and heterogeneity of the "other group". Furthermore, the final diagnosis was based on ¹⁸FDG-PET/CT results and the presence of additional symptoms (clinical, analytical and evolutionary data). For these reasons the patients were not labelled LVV.

Taken together, it is evident that the frequency of association between PMR and LVV differs significantly depending on the characteristics of the cohorts studied. The time of disease evolution, the treatment administered and the presence of new symptoms of LVV are variables that must be considered when describing the association between PMR and LVV studied by ¹⁸FDG-PET/CT.

Distribution of increased glucidic metabolism in ¹⁸FDG-PET/CT scan

In our study, the majority of patients diagnosed with PMR showed an increase in glucidic metabolism in the shoulders, followed by hips and peripheral joints. Almost half of the patients

showed uptake in a bursa. The most frequently affected peripheral areas were the sternoclavicular, followed by the carpus and the knees.

In a retrospective study of 50 PMR patients undergoing a ¹⁸F-DG-PET/CT scan, Sondag et al.²² found greater uptake in the shoulders than in the hips, with percentages of distribution that were very similar to ours (54% and 36% for shoulders and hips, respectively). Two other authors, Rehak et al.²³ and Henckaerts et al.¹², also observed greater uptake in the shoulders than in the hips, though their percentages were considerably higher than ours. Rehak et al. evaluated 67 patients and found that 87% and 70%, respectively, of the patients showed uptake in the shoulders and hips. Henckaerts et al. evaluated 67 patients and also described a greater uptake in the shoulders than the hips than in our study (97% in shoulders and 67% in hips compared with our figures of 54.8% and 37%, respectively). This higher percentage of hip and shoulder involvement in Rehak's and Henckaert's studies^{12,23} compared to our findings, as well as those reported by Sondag,²² could be because no patients in their study were undergoing steroid treatment.

We also analyzed the ¹⁸F-DG-PET/CT scan uptake frequency in bursae. We observed a 35.6% uptake in the ischial bursa in patients with PMR, frequencies that are lower than those described by the groups in the studies by Rehak²³, Sondag²² and Henckaerts¹², who found an uptake from 52% to 67% in patients with PMR. Likewise, we observed uptake in 30.1% and 34.2% of cervical and lumbar spinous processes, respectively. We also found a similar frequency and involvement when comparing lumbar and cervical processes. Rehak and Sondag found a greater involvement in lumbar processes (57% and 38% respectively) than in cervical processes (19.5% and 10% respectively). Interestingly, we found that dorsal processes were involved in 4.1% of patients, a finding that had not been described previously.

Our results showed peripheral joint uptake. This is controversial considering the possible differential diagnosis with EORA in patients with PMR. Although we describe 8.2% of involvement in knees and 10.95% in wrists, the final diagnosis of PMR stands, though not that of EORA. A few authors describe peripheral joint uptake in detail in patients with PMR^{24,25}. Kaneko et al.²⁶ studied 20 patients with PMR, describing an exceptionally high frequency of knee involvement (96.2%). However, only four patients complained of knee symptoms. The same group also described a high frequency of involvement of the wrists, with figures of up to

40%. Cimmino et al.²⁷ reported a higher frequency of knee involvement (84%) in a study using ¹⁸F-DG-PET/CT. On the other hand, in 2018, Yuge et al.²⁵ studied 16 patients with a definitive diagnosis of PMR and described a significant incidence (6%) of ¹⁸F-DG uptake in the wrists. Considering the small number of patients in these previous studies, it is difficult to reach a firm conclusion concerning peripheral uptake. We still need to define those findings in pure PMR and observe whether they can develop into EORA over time.

In our cohort, FDG-PET was helpful to rule out vasculitis, malignancy and peripheral arthritis. Nevertheless, the TBRs in the typical PMR locations (spine/shoulders/hips) did not differ significantly from those in the "other diagnosis" group. TBR at typical PMR locations can be similar in groups for two reasons. First, other diagnoses, such as LVV and neoplasms, can be accompanied by PMR, and second, the group of "other diagnoses" is small, making it more difficult to find statistically significant differences.

Limitations

This study has several limitations. The main limitation is its retrospective character. Nevertheless, our results clearly reflect observations in our daily clinical practice. Second, as some patients were under treatment with steroids at the time of the ¹⁸F-DG-PET/CT scan, our results cannot be compared statistically to studies involving steroid-naïve patients only. A third limitation is the lack of a control group. However, we would not have been able to compare the diagnosis found in patients with PMR using a ¹⁸F-DG-PET/CT scan with the general population for ethical and procedural reasons. Fourth, the inclusion of patients who concomitantly presented GCA symptoms may entail a bias.

Conclusion

Based on our findings, we consider the ¹⁸F-DG-PET/CT scan to be a very useful tool, not only to help diagnose PMR, but also to identify diseases such as LVV and malignant processes that are associated with this disorder. However, the best moment to perform this technique (PMR_{os} or PMR_{sr}) remains to be defined.

References

1. González-Gay MA, Matteson EL, Castañeda S. Polymyalgia rheumatica. *Lancet* 2017; 390:1700–1712.
2. Pipitone N, Salvarani C. Update on polymyalgia rheumatica. *Eur J Intern Med.* 2013; 24: 583–589.
3. Gonzalez-Gay MA, Garcia-Porrúa C, Salvarani C, et al. Diagnostic approach in a patient presenting with polymyalgia. *Clin Exp Rheumatol.* 1999; 17: 276–8.
4. Gonzalez-Gay MA, Garcia-Porrúa C, Salvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. *J Rheumatol.* 2000; 27: 2179–84.
5. Deal CL, Meenan RF, Goldenberg DL, et al. The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration. *Arthritis Rheum.* 1985; 28: 987–94.
6. Salvarani C, Cantini F, Macchioni P, et al. Distal musculoskeletal manifestations in polymyalgia rheumatica: a prospective followup study. *Arthritis Rheum.* 1998; 41: 1221–6.
7. Salvarani C, Gabriel SE, O'Fallon WM, et al. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. *Ann Intern Med.* 1995; 123: 192–4.
8. Gran JT, Myklebust G, Wilsgaard T, et al. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. *Rheumatology (Oxford)* 2001; 40:1238.
9. Gonzalez-Gay MA. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. *Semin. Arthritis Rheum.* 2004; 33: 289–93.
10. Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. *Ann Rheum Dis.* 2012; 71: 484–92.
11. Blockmans D, De Ceuninck L, Vanderschueren S, et al. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. *Rheumatology* 2006; 46: 672–677.
12. Henckaerts L, Gheysens O, Vanderschueren S, et al. Use of 18F-fluorodeoxyglucose

- positron emission tomography in the diagnosis of polymyalgia rheumatica-A prospective study of 99 patients. *Rheumatology (Oxford)* 2018; 57: 1908–1916.
13. Palard-Novello X, Querellou S, Gouillou M, et al. Value of (18)F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment. *Eur J Nucl Med Mol Imaging*. 2016; 43: 773–9.
 14. Muller S, Hider SL, Belcher J, et al. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. *Ann Rheum Dis*. 2014; 73: 1769–1773.
 15. Ji J, Liu X, Sundquist K, Sundquist J, et al. Cancer risk in patients hospitalized with polymyalgia rheumatica and giant cell arteritis: a follow-up study in Sweden. *Rheumatology (Oxford)* 2010; 49: 1158–63.
 16. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. *J Rheumatol*. 1993; 20: 1335–9.
 17. Myklebust G, Wilsgaard T, Jacobsen BK, et al. No increased frequency of malignant neoplasms in polymyalgia rheumatica and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls. *J Rheumatol*. 2002; 29: 2143–7.
 18. Pfeifer EC, Crowson CS, Major BT, et al. Polymyalgia Rheumatica and its Association with Cancer. *Rheumatology (Sunnyvale)*. 2015; Suppl 6: 003
 19. Lavado-Pérez C, Martínez-Rodríguez I, Martínez-Amador N, et al. (18)F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica. *Rev Esp Med Nucl Imagen Mol*; 34: 275–81
 20. Prieto-Peña D, Martínez-Rodríguez I, Loricera J, et al. Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. *Semin Arthritis Rheum*. 2019; 48: 720–727.
 21. González-Gay MA, García-Porrúa C, Vázquez-Caruncho M. Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. *J. Rheumatol* 1998; 25: 1750–5.
 22. Rehak Z, Vasina J, Nemeč P, et al. Various forms of 18F-FDG PET and PET/CT findings in patients with polymyalgia rheumatica. *Biomed Pap*. 2015; 159: 629–636.
 23. Yamashita H, Kubota K, Takahashi Y, et al. Whole-body fluorodeoxyglucose positron

- emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. *Mod Rheumatol.* 2012; 22: 705–11.
24. Sondag M, Guillot X, Verhoeven F, et al. Utility of 18F-fluoro-dexoxyglucose positron emission tomography for the diagnosis of polymyalgia rheumatica: a controlled study. *Rheumatology (Oxford)* 2016; 55: 1452–7.
25. Yuge S, Nakatani K, Yoshino K, et al. Diagnosing polymyalgia rheumatica on 18F-FDG PET/CT: typical uptake patterns. *Ann Nucl Med.* 2018; 32: 573–577.
26. Kaneko K, Suematsu E, Miyamura T, et al. Differences of articular and extra-articular involvement in polymyalgia rheumatica: A comparison by whole-body FDG-PET/CT. *Mod Rheumatol.* 2019; 7: 1–7.
27. Cimmino MA, Camellino D, Paparo F, et al. High frequency of capsular knee involvement in polymyalgia rheumatica/giant cell arteritis patients studied by positron emission tomography. *Rheumatology (Oxford)* 2013; 52: 1865–72.

